3,600 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Sanders Morris Harris LLC

Sanders Morris Harris LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 3,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $474,000.

A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after buying an additional 154 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Jazz Pharmaceuticals by 1.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 12,383 shares of the specialty pharmaceutical company’s stock valued at $1,314,000 after acquiring an additional 201 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Jazz Pharmaceuticals by 38.1% in the second quarter. Thrivent Financial for Lutherans now owns 19,720 shares of the specialty pharmaceutical company’s stock valued at $2,093,000 after purchasing an additional 5,440 shares during the last quarter. Marex Group plc bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $610,000. Finally, State of Wyoming lifted its position in shares of Jazz Pharmaceuticals by 21.4% during the 2nd quarter. State of Wyoming now owns 4,029 shares of the specialty pharmaceutical company’s stock worth $428,000 after purchasing an additional 709 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the sale, the director directly owned 20,449 shares in the company, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Rick E. Winningham sold 5,500 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total value of $994,730.00. Following the completion of the transaction, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. The trade was a 38.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 129,291 shares of company stock valued at $22,745,410 over the last 90 days. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research analyst reports. Bank of America raised their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. reduced their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday. UBS Group reissued a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Morgan Stanley raised their price target on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $200.47.

Jazz Pharmaceuticals Stock Down 2.8%

JAZZ opened at $164.91 on Thursday. The company has a market capitalization of $10.02 billion, a P/E ratio of -27.17, a P/E/G ratio of 3.85 and a beta of 0.30. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The firm’s fifty day moving average price is $152.76 and its two-hundred day moving average price is $130.51. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.